[Oral cytostatic agents in the prevention of urothelial carcinoma. Our experience].
Gelabert Mas
A
A
Arango Toro
O
O
Rosales Bordes
A
A
Coronado García
J
J
Fernández Zuazu
J
J
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000601:surgery; D003875:Drug Eruptions / Q000209:etiology*; D005533:Foot Dermatoses / Q000139:chemically induced; D006229:Hand Dermatoses / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care; D005641:Tegafur / Q000009:adverse effects / Q000032:analysis*; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery
D005641:Tegafur
Citostáticos orales en la profilaxis del carcinoma de urotelio. Nuestra experiencia.